Clinical Trial Update: Mitigation of Radiation Pneumonitis, Fibrosis and Heart Toxicity With Nicorandil in Lung Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating nicorandil to mitigate radiation-induced lung and heart toxicities in lung cancer patients, including radiation pneumonitis …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Fibrosis
• Radiation Pneumonitis
• Radiation-induced Heart Disease

Drugs mentioned

• Nicorandil (nicorandil)

Snippet

Sponsor: Taipei Medical University WanFang Hospital | Conditions: Radiation Pneumonitis | Phase 2 | Status: UNKNOWN